Regulatory Pfizer’s Hympavzi secures FDA expanded indications for haemophilia Pharmaceutical TechnologyPfizer has received approval from the FDA for an expanded indication of Hympavzi for the treatment of haemophilia A or B.HematologyRead full story pharminent June 9, 2026 (Last updated: June 9, 2026) Pharmaceutical Technology Pfizer has received approval from the FDA for an expanded indication of Hympavzi for the treatment of haemophilia A or B. Hematology Read full story Post navigation Previous: J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1BNext: ADA: AZ reveals oral GLP-1 data in obesity, diabetes Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026